federal_register: 2025-21501
Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API
This data as json
| document_number | title | type | abstract | publication_date | pub_year | pub_month | html_url | pdf_url | agency_names | agency_ids | excerpts | regulation_id_numbers |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-21501 | Medicare Program; Inflation Reduction Act (IRA) Medicare Drug Price Negotiation Program Final Guidance | Notice | The Centers for Medicare & Medicaid Services (CMS) is announcing the availability of CMS' final guidance for the third cycle of the Medicare Drug Price Negotiation Program (hereafter the "Negotiation Program"), the first cycle of renegotiation, and manufacturer effectuation of the maximum fair price (MFP) in 2026, 2027, and 2028 for the implementation of the Inflation Reduction Act of 2022 (IRA) (Pub. L. 117-169). This and other IRA-related guidance can be viewed on the dedicated IRA section of the CMS website at https:// www.cms.gov/inflation-reduction-act-and-medicare/ | 2025-11-28 | 2025 | 11 | https://www.federalregister.gov/documents/2025/11/28/2025-21501/medicare-program-inflation-reduction-act-ira-medicare-drug-price-negotiation-program-final-guidance | https://www.govinfo.gov/content/pkg/FR-2025-11-28/pdf/2025-21501.pdf | Health and Human Services Department; Centers for Medicare & Medicaid Services | 221,45 | The Centers for Medicare & Medicaid Services (CMS) is announcing the availability of CMS' final guidance for the third cycle of the Medicare Drug Price Negotiation Program (hereafter the "Negotiation Program"), the first cycle of renegotiation, and... |